“I'm hoping to increase that number this year, hopefully, as people, you know, grow more aware of of the town day because I think a lot of companies were not aware that we were organizing this event”
→ Read the source episode
Number of job interviews conducted during Bio Spain 2026 Talent Day (October 1) exceeds 125
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Laurent Levy predicts Nanobiotics will report randomized phase two lung cancer trial results before H1 2027
Narissa Kreyer predicts Alterna will conduct a clinical study in adult PKU patients demonstrating AP-003 protein generation and biomarker reduction
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.